Catalyst Financial Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Catalyst Financial Partners's VRTX Position: Q2 2026 in Review
Catalyst Financial Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q2 2026, selling an estimated $148K and leaving 1,320 shares worth $656K. The position accounts for 0.07% of the portfolio, ranked #173.
Catalyst Financial Partners first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $739K in Q1 2026. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Catalyst Financial Partners held 1,320 shares of Vertex Pharmaceuticals worth $656K as of Q2 2026.
- Catalyst Financial Partners sold 334 Vertex Pharmaceuticals shares in Q2 2026, an estimated $148K.
- Vertex Pharmaceuticals made up 0.07% of Catalyst Financial Partners's portfolio in Q2 2026, its #173 holding.
- Catalyst Financial Partners first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
- Catalyst Financial Partners's Vertex Pharmaceuticals position peaked at $739K in Q1 2026.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Catalyst Financial Partners's 13F filing for Q2 2026, filed 30 Jul 2026.